Mark A Goldsmith's Stock Transactions in Revolution Medicines, Inc.

Mark A Goldsmith, a director and officer of Revolution Medicines, Inc., has filed a Form 144 indicating his intention to sell 10,000 shares of common stock acquired through the exercise of stock options. The transaction is scheduled for October 16, 2025, with an aggregate market value of $495,600. Additionally, Goldsmith recently sold 13,411 shares on September 16, 2025, generating gross proceeds of $614,557.73. The shares are traded on NASDAQ, and the broker involved is Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also notes that the stock option plan was adopted on December 19, 2024.